Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Swiss National Bank

Swiss National Bank raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 253,500 shares of the company’s stock after purchasing an additional 2,800 shares during the period. Swiss National Bank’s holdings in Denali Therapeutics were worth $5,166,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Quest Partners LLC purchased a new stake in Denali Therapeutics in the 3rd quarter valued at about $73,000. PNC Financial Services Group Inc. increased its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. KBC Group NV raised its stake in shares of Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after acquiring an additional 2,731 shares during the period. AlphaQuest LLC boosted its position in shares of Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after purchasing an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. increased its holdings in Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock valued at $204,000 after purchasing an additional 2,436 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the transaction, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the sale, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $14.76 on Tuesday. Denali Therapeutics Inc. has a 12 month low of $14.01 and a 12 month high of $33.33. The firm has a market capitalization of $2.14 billion, a PE ratio of -5.35 and a beta of 1.46. The business’s fifty day moving average price is $19.59 and its 200 day moving average price is $23.54.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on DNLI shares. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research note on Friday, February 28th. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Morgan Stanley started coverage on Denali Therapeutics in a research report on Friday, March 7th. They issued an “overweight” rating and a $33.00 target price for the company. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, B. Riley restated a “buy” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.